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both injections, by means of the Heroin Craving Question-
naire.  Results: Compared to saline, DAM administration in-
duced a significant decrease in plasma ACTH (p  ! 0.01), se-
rum cortisol (p  ! 0.0001) and saliva cortisol (p  ! 0.01), as well 
as in craving (p  ! 0.0001), over time.  Conclusion: Since acute 
DAM administration suppresses the stress response, DAM-
assisted treatment may be an effective alternative to metha-
done maintenance in stress-sensitive heroin-dependent pa-
tients.  Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Opioid dependence is a chronic relapsing brain disor-
der characterized by compulsive seeking and use of opi-
oids despite the negative consequences  [1] . Drug-related 
cues, stress or negative mood are associated with craving 
 [2–5] . Several previous studies have shown the relevance 
of stress and hypothalamic-pituitary-adrenal (HPA) axis 
dysfunction in substance use disorders  [6–11] .
 The first findings on the suppression of adrenocortical 
functions in opiate dependence were reported by Eisen-
man et al.  [12, 13] in the 1950s and 1960s in Lexington, 
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 Abstract 
 Background/Aim: Heroin dependence is a chronic relapsing 
disorder characterized by the compulsion to seek and use 
heroin. Stress and craving are seen as key factors for heroin 
use. Moreover, altered hypothalamic-pituitary-adrenal (HPA) 
axis function has been frequently reported. However, the 
acute effects of diacetylmorphine (DAM) on HPA axis activity 
and craving have not been investigated in a controlled study. 
The present randomized controlled study examined wheth-
er DAM administration differs from placebo (saline) adminis-
tration with regard to HPA axis response and heroin craving. 
 Methods: In a crossover experiment, 28 DAM-maintained 
heroin-dependent patients were first injected with DAM and 
then saline, or the converse. Plasma adrenocorticotropic 
hormone (ACTH) and cortisol in saliva and serum were mea-
sured at baseline and 20 and 60 min after both injections. 
Heroin craving was measured at baseline and 60 min after 
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Ky., USA. They found reduced urinary levels of 17-keto-
steroids  [12] and reduced plasma levels of 17-hydroxycor-
ticosteroids  [13] during a period of addiction in men, in 
comparison to a phase of nonaddiction. Moreover, these 
levels increased upon discontinuation of morphine. After 
detoxification, these levels returned to the preaddiction 
range  [12, 13] , indicating that stress hormone secretion 
was depressed during opioid addiction and elevated dur-
ing withdrawal. Further research has shown that opioids 
administered during surgery suppress HPA axis activity 
 [14, 15] . Furthermore, heroin-dependent subjects exhib-
ited lower plasma levels of adrenocorticotropic hormone 
(ACTH) and cortisol when compared with healthy indi-
viduals  [14, 16] , thus providing further evidence that HPA 
axis activity is suppressed during active opioid depen-
dence. On the other hand, recent studies suggest that sub-
stance use disorders are associated with elevated cortisol 
levels and depressive symptoms  [17] . The increased HPA 
axis activity might constitute a vulnerability to the devel-
opment of substance use disorders and relapse, and this 
relationship seems to be influenced by stressful life expe-
riences  [18, 19] .
 The altered HPA axis function in substance use dis-
orders is related to early life stress  [20, 21] . Patients re-
porting childhood trauma showed increased cortisol 
and decreased ACTH concentrations during withdraw-
al, which possibly reflect a persistent blunting of the HPA 
axis function as well as its hypersensitive reaction to 
acute stress in traumatized, alcohol-dependent patients 
 [20] . Moreover, higher cortisol and ACTH plasma levels 
were found in abstinent heroin- and cocaine-dependent 
patients in comparison to healthy control subjects with-
out a history of illicit drug use and childhood trauma 
 [21] .
 Opioid withdrawal is associated with increased stress 
hormone levels  [22] . Research on opioid antagonists (e.g. 
naloxone) further supports this finding  [23, 24] . Howev-
er, elevated stress reactivity was also found in currently 
abstinent, formerly heroin-dependent individuals not 
under opioid maintenance, which could be related to 
heightened craving and relapse  [25–27] . Opioid agonists, 
on the other hand, are associated with a reduction in 
stress hormone secretion  [28, 29] . In preliminary studies, 
our group also found that opioids suppress cortisol con-
centrations in heroin-dependent patients and reduce 
craving after methadone administration  [30, 31] . 
 Although previous findings have consistently shown 
that HPA axis function is modified in heroin dependence 
and that opioids suppress stress hormone release, there 
have been few experimental studies and these have gener-
ally focused on the effects of methadone  [28, 29] . How-
ever, methadone maintenance treatment (MMT) is not 
the only treatment for severe heroin dependence, as her-
oin-assisted treatment (HAT), involving the prescription 
of pharmaceutical heroin (diacetylmorphine, DAM), 
medical attendance and psychosocial support, is also ef-
fective  [32] . Chronic heroin-dependent patients who ini-
tially do not benefit sufficiently from MMT and absti-
nence-oriented (drug-free) treatments respond well to 
treatment with DAM and improve significantly in terms 
of mental and physical health and psychosocial function-
ing, mainly assessed as reduction in crime and concur-
rent use of illegal substances  [33–39] .
 The present randomized controlled trial examined 
HPA axis function in opioid dependence after DAM ad-
ministration. Our aim was to investigate the acute effects 
of DAM on HPA axis activity, subjective craving and 
withdrawal symptoms in chronic heroin-dependent pa-
tients. We hypothesized that DAM would suppress ACTH 
and cortisol concentrations and heroin craving, in con-
trast to the increases in these parameters observed during 
withdrawal.
 Materials and Methods 
 Study Sample 
 Twenty-eight patients (67.9% men, n = 19) were recruited from 
patients at the Division of Substance Use Disorders of the Psychi-
atric Hospital of the University of Basel. They were aged 23–58 
years (mean age 41.3 years, SD 6.6), met the DSM-IV diagnostic 
criteria for opioid dependence and had been in HAT for a mean 
period of 6.7 years (SD 4.5). Exclusion criteria included a positive 
breath alcohol test and a history of significant medical problems 
or major mental disorders (other than substance use and person-
ality disorders). All patients received written information on the 
examination protocol and gave their written consent. The study 
was approved by the local ethics committee.
 Procedure 
 The present study is a part of a randomized controlled clinical 
trial. It has been registered on the website http://clinicaltrials.gov 
(ID NCT01174927). All patients were submitted to both condi-
tions in a crossover design. The sequence of the injected substanc-
es [DAM and saline (NaCl) as placebo] was randomized. One 
group (n = 14) first received their daily dose of DAM before the 
beginning of the experiment, whereas the second group (n = 14) 
first received placebo (NaCl). The patients were blinded to the 
substance. DAM was provided by the Swiss Federal Office of Pub-
lic Health in the form of the hydrochloride salt. This was dissolved 
in water (1: 9) on site and aspirated into a syringe, which was 
adapted to the evacuated infusion system. Patients of the second 
group were given their daily dose of DAM immediately after the 
experiment. The test period lasted approximately 2.5 h, including 
stressful stimuli during a functional magnetic resonance imaging 
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(fMRI) examination. One week later, the patients completed the 
alternative treatment, with the opposite sequence of substance in-
jections. Both sessions were performed in the morning.
 Biochemical Measurements 
 ACTH and cortisol were taken as measures of the stress re-
sponse. Samples were collected at baseline (at least 1 h after awak-
ening, 7.30 a.m.) and 20 min (9.00 a.m.) and 60 min after sub-
stance administration (10.30 a.m.). Salivary cortisol was analyzed 
with a time-resolved immunoassay with fluorescence detection, 
as described elsewhere  [30] . Total cortisol concentrations were 
measured in serum with the Immulite 2000 cortisol test (Siemens, 
Germany). ACTH was measured in EDTA plasma with the ACTH 
Immulite test (Siemens). Interassay and intra-assay coefficients of 
variance were below 10% for all analyses. 
 Psychological Measurements 
 Psychological data were collected at the beginning and the end 
of the experiment. The Heroin Craving Questionnaire (HCQ) 
 [40] was used to measure heroin craving. A reliability of   = 0.94 
was calculated. The corresponding scale contains 9 items and 
measures the desire to use heroin.
 In order to detect possible placebo effects, 3 min after the sub-
stance administration the patients were asked which substance 
they believed they had received, i.e. DAM or placebo. Addition-
ally, both subjective drug effects and withdrawal symptoms were 
measured using a visual analogue scale (0 = none, 10 = very strong).
 Statistical Analyses 
 For each of the outcome variables (plasma ACTH, serum cor-
tisol, salivary cortisol concentrations), a two-factorial repeated-
measures analysis of variance (ANOVA) was calculated, with two 
within-subject substances (DAM/placebo) and the between-sub-
jects group membership (sequence of the administered substanc-
es). Cocaine use was included in the analyses as a covariate. In 
order to take the large range of individual baseline hormone levels 
into account, ANOVAs were carried out with the differences be-
tween the baseline and post-trial measurements (i.e. before and 
60 min after substance injection). To evaluate the stress hormone 
changes across the 3 measurement points under both conditions 
(baseline and 20 and 60 min after substance injection), pairwise 
contrasts of the hormone levels were calculated. For the non-nor-
mally distributed variables, a nonparametric analysis (Fried-
man’s ANOVA with Wilcoxon signed-rank post hoc tests) was 
calculated. The Bonferroni correction was used to correct for the 
  -error accumulation.
 Psychometric data (HCQ scores and subjective rating of drug 
effects and withdrawal symptoms) were analyzed with the t test 
and, where appropriate, with a nonparametric test (Wilcoxon 
signed-rank test) for dependent samples. 
 All analyses were computed with the statistical program SPSS 
19.0. Graphs were created with SigmaPlot 11.0. The two-tailed sig-
nificance level was set to p  ! 0.05.
 Results 
 Demographic and Clinical Variables 
 As shown in  table 1 , 8 patients (28.6%) tested positive 
for cannabis and 15 patients (53.6%) for cocaine at one or 
both measurements. No significant differences were ob-
served between the two groups in terms of diagnostic and 
sociodemographic variables (p  1 0.05).  Table 1 gives an 
overview of the characteristics of our patient sample.
 Drug Effects, Withdrawal Symptoms and Heroin 
Craving 
 As expected, significantly more drug effects and fewer 
withdrawal symptoms were reported after injection of 
DAM than with placebo (p  ! 0.0001). Only one placebo 
effect was observed, as one patient rated NaCl as DAM.
 No significant differences between HCQ scores at 
baseline (i.e. before any substance administration) were 
found (p  1 0.05). Before and after placebo injection, HCQ 
scores did not differ significantly either (p  1 0.05). How-
ever, after DAM administration, craving dropped signif-
icantly over time (t = 5.19, degrees of freedom = 27; p  ! 
0.0001). Compared with placebo, significantly lower 
craving was reported at the end of the sequence when pa-
tients received DAM (t = –5.63, degrees of freedom = 27; 
p  ! 0.0001) ( fig. 1 ).
 At the end of the experiment (i.e. 60 min after sub-
stance injection), HCQ scores were significantly associ-
ated with changes in ACTH secretion. As expected, ma-
jor heroin craving was positively related with increased 
Table 1. S ociodemographic and diagnostic characteristics of the 
study sample (n = 28)
Characteristic Mean SD
Age, years 41.3 6.6
Male gender 19 (67.9)
Education, years 10.4 2.5
In relationship 9 (32.1)
Employed 11 (39.3)
Disability 9 (32.1)
Doses of DAM, mg/day 318.6 131.7
Methadone maintenance 13 (46.4)
Doses of methadone, mg/day 13.4 17.4
Duration of dependence, years 20.8 6.6
Age at first-time heroin use, years 19.0 3.4
Duration of opioid maintenance, years 6.7 4.5
Substance abuse
Tobacco 28 (100.0)
Number of cigarettes/day 21.0 9.1
Cocaine 15 (53.6)
Cannabis 8 (28.6)
V alues in parentheses represent percentages.
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ACTH concentrations when patients received placebo 
(r = 0.30; p  ! 0.05). No other significant correlation was 
found between the subjective craving scores and the hor-
monal stress response (p  1 0.05). 
 HPA Axis Activity 
 DAM significantly suppressed hormone concentra-
tions, as follows: ACTH, F(1, 25) = 8.54, p =  0.007; cortisol 
serum, F(1, 25) = 30.69, p  ! 0.0001, and cortisol saliva, F 
(1, 25) = 11.83, p =  0.002. No significant effects on the 
hormone levels of cocaine use or group membership were 
observed (p  1 0.05) ( table 2 ).
 The pairwise comparisons of the hormone levels 
showed significant reductions in plasma ACTH, serum 
cortisol and saliva cortisol concentrations over time after 
DAM administration (p  ! 0.0001). After placebo admin-
istration, only plasma ACTH increased significantly, be-
tween 20 and 60 min after the injection (p  ! 0.01). Corti-
sol levels did not increase significantly after placebo in-
jection (p  1 0.05). No significant differences between the 
baseline hormone levels were found (p  1 0.05) ( fig. 2–4 ).
 Discussion 
 The present study examined the acute effects of DAM 
(pharmaceutical heroin) on HPA axis function and her-
oin craving in a controlled experimental setting. There 
were significant decreases in ACTH and cortisol concen-
trations and in HCQ scores with DAM in comparison to 
placebo, demonstrating that DAM suppressed HPA axis 
activity and reduced heroin craving in chronic heroin-
dependent, DAM-maintained patients.
 The suppressive effect of opioids in general  [12–16] 
and of methadone in particular  [25, 30] on stress hor-
mone secretion and subjective craving has already been 
shown. Our recent uncontrolled study also found re-
duced cortisol concentrations in heroin-dependent pa-
tients after they had received DAM  [31] . This has now 
been confirmed for the first time in a randomized, con-
trolled, crossover study. There was no significant interac-
tion between the injected substance and concurrent co-
caine use or the sequence of administration, indicating 
that the suppression of the HPA axis is solely due to DAM 
administration, there is no significant carryover effect 
and cocaine abuse is irrelevant  [41] . Our results thus con-
firm the attenuating effect of acute opioid administration 
on the HPA axis response. Further studies should inves-
tigate whether maintenance treatment with DAM also 
normalizes diurnal stress hormone secretion in opioid-
dependent patients.
 In previous studies, opioid withdrawal was associated 
with increased stress hormone secretion  [22–24] . How-
ever, in contrast to the highly significant continuous de-
cline in the hormone concentrations after DAM admin-
istration, the increase in the hormone levels after placebo 
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 Fig. 1. Patients’ subjective craving (Desire to Use Heroin scale, 
HCQ) before and after substance administration. Means and 
standard errors are displayed.  * * *  p  ! 0.0001, n.s. = not signifi-
cant. 
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 Fig. 2. ACTH concentration in DAM (heroin)-maintained pa-
tients after DAM (heroin) or placebo (saline) injection. Means 
and standard errors are displayed.  * *  p  ! 0.01,  * * *  p  ! 0.0001. 
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in our study was slight or nonsignificant. Only ACTH 
levels increased significantly between 20 and 60 min after 
placebo injection, but the main time effect was nonsig-
nificant as well. Hence, our findings do not support the 
idea that opioid withdrawal is associated with activation 
of the HPA axis. These results can possibly be explained 
by the patients’ long-standing heroin-assisted treatment 
(HAT). Moreover, patients in both groups knew that they 
would receive their daily DAM dose at the end of the ex-
periment at the latest. Although they reported withdraw-
al symptoms, they may not have experienced intense so-
matic withdrawal. Wisniewski et al.  [17] found elevated 
Table 2.  ANOVA for the effects of the substance (DAM) on stress hormone levels and the interactions between substance and cocaine 
abuse and between substance and group membership
SS d.f. MS F p value
ACTH
Substance 12,696.98 1 12,696.98 8.54 0.007
Substance ! cocaine abuse 681.45 1 681.45 0.46 0.505
Substance ! group 960.19 1 960.19 0.65 0.429
Error (substance) 37,151.20 25 1,486.05
Cortisol serum
Substance 515,684.12 1 515,684.12 30.69 0.000
Substance ! cocaine abuse 7,042.94 1 7,042.94 0.42 0.523
Substance ! group 2,352.60 1 2,352.60 0.14 0.711
Error (substance) 420,064.11 25 16,802.56
Cortisol saliva
Substance 7,131.07 1 7,131.07 11.83 0.002
Substance ! cocaine abuse 3.76 1 3.76 0.01 0.938
Substance ! group 1,916.02 1 1,916.02 3.18 0.087
Error (substance) 15,070.16 25 602.81
S S = Sum of squares; d.f. = degrees of freedom; MS = mean square; ! = interaction.
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 Fig. 3. Serum cortisol concentration in DAM (heroin)-main-
tained patients after DAM (heroin) or placebo (saline) injection. 
Means and standard errors are displayed.  *   p  ! 0.05,  * * *   p  ! 
0.0001. 
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 Fig. 4. Saliva cortisol concentration in DAM (heroin)-maintained 
patients after DAM (heroin) or placebo (saline) injection. Means 
and standard errors are displayed.  * * *  p  ! 0.0001, n.s. = not sig-
nificant. 
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basal cortisol levels in active drug users, which might re-
flect withdrawal symptoms during the study as well as 
the combination of heroin and cocaine commonly used 
by illicit drug users. Therefore, in our study the regular-
ity of DAM administration and its availability, as well as 
other psychological factors associated with the HAT, in-
cluding psychosocial support, may have been relevant 
factors influencing the patients’ stress response, resulting 
in relative stability of stress hormone secretion during the 
experiment, even in the placebo condition. The associa-
tion between opioid withdrawal and HPA axis activity in 
heroin-dependent patients should next be examined by 
including heroin-dependent individuals without opioid 
maintenance treatment.
 The significant correlation between the craving 
scores and the changes in ACTH levels at the end of the 
experiment showed the relationship between the pa-
tients’ subjective feeling and their endocrine response, 
suggesting that the greater the subjective withdrawal, 
the higher the stress hormone concentrations and vice 
versa. However, this relationship does not allow the con-
clusion that changes in the HPA response have a signif-
icant impact on the subjective experience of craving. 
Nevertheless, based on the consistent previous findings 
that opioid withdrawal is associated with increased 
stress hormone release  [22–24] , the elevated ACTH lev-
els might be a possible explanation for the higher subjec-
tive craving scores. 
 The advantages of the present study are its random-
ized, controlled, crossover design and the adequate sam-
ple size, which allowed for the control of confounding 
variables and sequence effects. On the other hand, the 
stressful stimuli presented in the fMRI session were not 
a valid stress test (such as the Trier Social Stress Test  [42] ). 
However, performance tasks which could be unfavorably 
evaluated by others, as used here, constitute psychologi-
cal stress, and the relevance of such tasks to increased 
cortisol and ACTH responses has already been shown 
 [43] . Most notably, fMRI scanning has been demonstrat-
ed to be a stressful experience associated with elevated 
cortisol concentrations in healthy persons and depressive 
patients  [44–46] . In substance use disorders, psychoso-
cial stress is generally considered to be a predictive factor 
for relapse  [19, 47, 48] .
 Several previous studies have established positive ef-
fects of DAM maintenance in heroin dependence in pa-
tients for whom MMT or abstinence-orientated (drug-
free) therapy had been unsuccessful  [32, 33, 35–39] . De-
spite the above-mentioned limitations, the present study 
supports the efficacy of HAT and provides potential evi-
dence for clinical implications. MMT-resistant patients 
who seem to react strongly to stress may possibly profit 
in particular from DAM maintenance. Short-acting opi-
oids (e.g. heroin) seem to lessen the heightened stress re-
activity and desire for heroin, as observed in former her-
oin users without opioid maintenance treatment  [25–27] , 
and might thereby prevent relapse with its serious conse-
quences. However, based on the intravenous administra-
tion of DAM, there is a greater risk of negative side effects 
in HAT (respiratory depression, epileptic seizure)  [36, 38, 
49] . Under medical supervision and with an adequate 
waiting period after DAM injection, such incidents can 
be avoided, so that the safety and efficacy of the treatment 
remain assured. In addition to the injectable form, oral 
administration as a tablet is possible  [50] .
 HAT is an established treatment form for severe opi-
oid dependence in Switzerland and the Netherlands  [32] . 
For those chronic heroin-dependent patients who ini-
tially do not profit from other treatments, it is an effec-
tive alternative treatment and complements the thera-
peutic spectrum for opioid dependence  [51] . Moreover, 
recent research has indicated the efficacy of HAT even in 
heroin-dependent patients with no previous mainte-
nance experience  [52] . A better understanding of the 
acute effects of DAM (heroin) would therefore promote 
the optimization of the treatment for chronic opioid de-
pendence.
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